Lexington, MA - January 31, 2008 – Predictive Biosciences, an emerging venture developing intervention diagnostic products for informed cancer management™, today announced that Dr. Martin Madaus has joined the Company's Board of Directors.
"Martin brings to the Predictive Board of Directors proven experience in developing and commercializing diagnostics. His extensive industry and management expertise will provide Predictive a substantial advantage in delivering next-generation cancer management technologies to the marketplace," said Eugene Chiu, Predictive Biosciences Vice President of Business Development and Co-founder.
Dr. Madaus currently serves as President, CEO and Chairman at Millipore Corporation. Millipore is a leader in the life science industry, providing multi-disciplinary scientific expertise and a broad portfolio of leading edge technologies, tools and services for bioscience research and biopharmaceutical manufacturing.
"I am very excited about working with the Predictive team to realize their vision for the future of cancer management with non-invasive, intervention diagnostics," said Dr. Madaus.
Dr. Madaus came to Millipore from Roche Diagnostics Corporation where, as President and Chief Executive Officer (2000-2004), he was responsible for the North American Operations. Prior to that, he was Vice President of Business Development for Roche Molecular Diagnostics. Dr. Madaus joined Roche in 1998 when he was general manager of Boehringer Mannheim Canada, through the acquisition of Boehringer Mannheim by Roche. From 1989 to 1998, Dr. Madaus worked at Boehringer Mannheim in senior management, sales and marketing, and product management roles both in Germany and in the United States.
Dr. Madaus is a director of the Massachusetts High Technology Council, the New England Healthcare Institute, the Massachusetts Workforce Development Investment Board, and the YMCA of Greater Boston. He has served on the Board of Directors of AdvaMed and was Chair of its In Vitro Diagnostic working committee.
About Predictive Biosciences
Leveraging its portfolio of patented biomarkers and clinical algorithms, Predictive Biosciences is pioneering intervention diagnostic assays for informed cancer management™. The company's proprietary clinical algorithms, which deliver exceptionally high negative predictive value (NPV) and positive predictive value (PPV), can be applied to significantly enhance the performance of biomarkers and diagnostic assays. Predictive Biosciences is privately funded by Highland Capital Partners and IDG Ventures Boston and is based in Lexington, MA. For more information and partnership inquiries, visit Predictive Biosciences' website at www.predictivebiosci.com.